Chinese drug maker Innogen Pharmaceutical Technology has raised $120 million in a new funding round to speed up the development and clinical trials of drug candidates, as well as the construction of its production base.

The startup will build a drug production base in compliance with the cGMPs, or current good manufacturing practices, which are guidelines set by the regulator to assure proper design, monitoring, and control of drug manufacturing processes and facilities. Founded in 2015, the Chinese startup is growing in a market with the world’s largest number of diabetes patients.

https://www.innogen.ac.uk/

Drug Maker Innogen Closes $120M To Tap Into China’S Diabetes Market

Description

Company Information

Funding Insights

Drug Maker Innogen Closes $120M To Tap Into China’S Diabetes Market

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information